Serum Calprotectin (S100A8/A9): A Promising Biomarker in Diagnosis and Follow-up in Different Subgroups of Juvenile Idiopathic Arthritis
Abstract BackgroundManagement of juvenile idiopathic arthritis (JIA) lacks of diagnostic and prognostic biomarkers. Therefore, this study was designed to assess the use of serum calprotectin (sCal) as a marker of disease activity and its monitoring, and as a classification and prognosis tool of response to treatment or risk of flares in patients with JIA. MethodsEighty-one patients with JIA from the CAP48 multicentric cohort were included in this study, as well as 11 healthy controls. Enzyme-linked immunosorbent assay (ELISA) method was used to quantify sCal with a commercial kit. Mann-Whitney tests were used to compare results, correlations were assessed with Spearman’s rank correlation coefficients and Receiver Operating Characteristic curves were also generated to evaluate serum calprotectin as a prognostic tool.ResultsPatients with an active disease compared to healthy controls and to patients with inactive disease showed an 8-fold and a 2-fold increased level of sCal respectively. sCal was found to be correlated with the CRP and even more strongly with the ESR. Evolution of DAS28 scores correlated well with evolution of sCal, as opposed to evolution of CRP. As for the CRP, sCal could differentiate forms with active oligoarthritis from polyarthritis or systemic forms. However, sCal brought an added value compared to the CRP as a prognosis marker. Indeed, patients with active disease and good responder to treatment (pediACR > 30) at 6 months following the sample test had higher sCal levels, while patients with inactive disease had higher sCal levels in case a flare was observed up to 3 to 9 months following the sample test.ConclusionsThis study confirms the potential uses of serum calprotectin as a biomarker in diagnosis and follow-up in JIA..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
ResearchSquare.com - (2021) vom: 05. Jan. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
La, Céline [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.21203/rs.3.rs-138436/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA034261265 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA034261265 | ||
| 003 | DE-627 | ||
| 005 | 20230429192844.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220113s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-138436/v1 |2 doi | |
| 035 | |a (DE-627)XRA034261265 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-138436/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a La, Céline |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum Calprotectin (S100A8/A9): A Promising Biomarker in Diagnosis and Follow-up in Different Subgroups of Juvenile Idiopathic Arthritis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract BackgroundManagement of juvenile idiopathic arthritis (JIA) lacks of diagnostic and prognostic biomarkers. Therefore, this study was designed to assess the use of serum calprotectin (sCal) as a marker of disease activity and its monitoring, and as a classification and prognosis tool of response to treatment or risk of flares in patients with JIA. MethodsEighty-one patients with JIA from the CAP48 multicentric cohort were included in this study, as well as 11 healthy controls. Enzyme-linked immunosorbent assay (ELISA) method was used to quantify sCal with a commercial kit. Mann-Whitney tests were used to compare results, correlations were assessed with Spearman’s rank correlation coefficients and Receiver Operating Characteristic curves were also generated to evaluate serum calprotectin as a prognostic tool.ResultsPatients with an active disease compared to healthy controls and to patients with inactive disease showed an 8-fold and a 2-fold increased level of sCal respectively. sCal was found to be correlated with the CRP and even more strongly with the ESR. Evolution of DAS28 scores correlated well with evolution of sCal, as opposed to evolution of CRP. As for the CRP, sCal could differentiate forms with active oligoarthritis from polyarthritis or systemic forms. However, sCal brought an added value compared to the CRP as a prognosis marker. Indeed, patients with active disease and good responder to treatment (pediACR > 30) at 6 months following the sample test had higher sCal levels, while patients with inactive disease had higher sCal levels in case a flare was observed up to 3 to 9 months following the sample test.ConclusionsThis study confirms the potential uses of serum calprotectin as a biomarker in diagnosis and follow-up in JIA. | ||
| 700 | 1 | |a Lê, Phu Quoc |e verfasserin |4 aut | |
| 700 | 1 | |a Ferster, Alina |e verfasserin |4 aut | |
| 700 | 1 | |a Goffin, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Spruyt, Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Lauwerys, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Durez, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Boulanger, Cecile |e verfasserin |4 aut | |
| 700 | 1 | |a Sokolova, Tatiana |e verfasserin |4 aut | |
| 700 | 1 | |a Rasschaert, Joanne |e verfasserin |4 aut | |
| 700 | 1 | |a Badot, Valérie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2021) vom: 05. Jan. |
| 773 | 1 | 8 | |g year:2021 |g day:05 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-138436/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 05 |c 01 | ||
| 953 | |2 045F |a 570 | ||